Faculté des Sciences de Santé, Université Bourgogne Franche-Comté, 21000 Dijon, France.
Team "CAdIR", CRI INSERM UMR1231 "Lipids, Nutrition and Cancer", 21000 Dijon, France.
Int J Mol Sci. 2021 May 4;22(9):4871. doi: 10.3390/ijms22094871.
During tumor growth, angiogenesis is required to ensure oxygen and nutrient transport to the tumor. Vascular endothelial growth factor (VEGF) is the major inducer of angiogenesis and appears to be a key modulator of the anti-tumor immune response. Indeed, VEGF modulates innate and adaptive immune responses through direct interactions and indirectly by modulating protein expressions on endothelial cells or vascular permeability. The inhibition of the VEGF signaling pathway is clinically approved for the treatment of several cancers. Therapies targeting VEGF can modulate the tumor vasculature and the immune response. In this review, we discuss the roles of VEGF in the anti-tumor immune response. In addition, we summarize therapeutic strategies based on its inhibition, and their clinical approval.
在肿瘤生长过程中，需要血管生成来确保肿瘤的氧气和营养物质的运输。血管内皮生长因子 (VEGF) 是血管生成的主要诱导因子，似乎是抗肿瘤免疫反应的关键调节剂。事实上，VEGF 通过直接相互作用以及通过调节内皮细胞或血管通透性上的蛋白表达来间接调节先天和适应性免疫反应。VEGF 信号通路的抑制已在临床上获准用于治疗多种癌症。针对 VEGF 的治疗方法可以调节肿瘤血管生成和免疫反应。在这篇综述中，我们讨论了 VEGF 在抗肿瘤免疫反应中的作用。此外，我们总结了基于其抑制的治疗策略及其临床批准情况。
